Oslo Cancer Cluster aims to enhance the visibility of oncology innovation made in Norway by being a significant partner for international clusters, global biopharma companies and academic centres. – Our goal is to support our members in their effort to attract international partners, investments and successful academia-industry collaborations, says International Advisor Jutta Heix. Heix is […]
Author Archive for: oslocancer
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 275 entries.
Entries by oslocancer
Our newest board members are officially introduced! On the 24th of May in 2017, the general assembly meeting took place and fatefully decided Oslo Cancer Cluster’s newest board members. These members, despite having some big seats to fill, will take on a respectful duty belonging to the board: where professionals in the field function as the […]
Doctors, researchers and audience gather at breakfast to learn about genetics, data and how working together will help beat cancer. The time is 8:15. Many have started to file in and shuffle to their seats while chatting and occasionally sipping their first morning coffee. As it starts to quiet down, the lights are dimmed, the […]
A driving force behind the collaboration between Ullern Upper Secondary School and Oslo Cancer Cluster is stepping down. This is her adventure. After fifteen great and productive years at Ullern Upper Secondary School, Esther Eriksen steps down from her position as vice principle in the upcoming month. Esther, who has been responsible for many various […]
The cluster-to-cluster project PERMIDES stimulates collaboration between biotech companies and IT companies. Its goal is to develop more innovative, personalized cancer treatments. Oslo Cancer Cluster is currently involved in a big European collaboration through the cluster-to-cluster project PERMIDES. 24 May you can benefit from the project by joining the BIOMED INFORMATICS workshop in Oslo. This workshop […]
Oslo Cancer Cluster Incubator stakk av med Siva-prisen for 2017 på årets Siva-konferanse i Trondheim. Slik beskriver Siva vinneren: Oslo Cancer Cluster Incubator er en pådriver til utvikling av diagnostikk og behandling av kreftpasienter ved hjelp av ny revolusjonerende teknologi. De jobber med å omsette kreftforskning til nye medisiner og behandlingsformer. Dette gir nytt håp for kreftpasienter og […]
Thermo Fisher Scientific is one of three finalists to win the award and title in Oslo this Tuesday. The technology which the biotech company is nominated for, is development of faster and cheaper DNA-sequencing. More than 70 companies were candidates for this year’s price, according to the Norwegian online tech magazine Teknisk Ukeblad. Thermo Fisher Scientific is one […]
En ny rapport om helsenæringens verdi er ute. Du kan laste ned rapporten her. Oslo Cancer Cluster er del av et konsortium som ønsker en oversikt over helsenæringens tilstand i Norge. Helseindustrien er en ung næring i Norge. Derfor måles den ikke som andre næringer av Statistisk Sentralbyrå. Dette er grunnen til at konsortiet har […]
Oslo Cancer Cluster member Roche has received approval for a medication against a specific form for lung cancer by the Norwegian Medicines Agency. Clinical data from a phase III study of the lung cancer medicine, named Alecensa, also shows significant approved survival for lung cancer patients. This is important news for younger lung […]
Join six pupils from Ullern Upper Secondary School to see how physics plays a crucial role in good cancer treatment. A group of interested pupils pay close attention as Taran Paulsen Hellebust explains the recommended radiation dose for a patient with prostate cancer. On a big monitor, she shows how the dose administered by the radiotherapy […]
Contact Team >
Oslo Cancer Cluster Innovation Park opened in May 2015.
The Innovation Park brings together the oncology-value chain from basic research to industry within the Oslo-area.
Our vision is to create Europe's leading environment for education, research and industry within oncology, shortening the development time of new cancer treatments.